Inspire Investing LLC increased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 101.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,667 shares of the biotechnology company's stock after acquiring an additional 32,645 shares during the quarter. Inspire Investing LLC's holdings in ADMA Biologics were worth $1,293,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of ADMA. Contravisory Investment Management Inc. acquired a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $216,000. USA Financial Formulas boosted its stake in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after buying an additional 539 shares during the last quarter. CWM LLC grew its holdings in ADMA Biologics by 72.5% in the 3rd quarter. CWM LLC now owns 14,129 shares of the biotechnology company's stock valued at $282,000 after buying an additional 5,937 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of ADMA Biologics in the 2nd quarter worth $6,468,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $230,000. Hedge funds and other institutional investors own 75.68% of the company's stock.
NASDAQ ADMA opened at $17.15 on Monday. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $21.13. The stock has a market capitalization of $3.98 billion, a P/E ratio of -857.25 and a beta of 0.62. The firm's 50-day moving average is $17.72 and its two-hundred day moving average is $12.36. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts' expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm's quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.02) EPS. On average, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.
A number of brokerages recently issued reports on ADMA. Mizuho upped their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a "buy" rating in a report on Thursday, June 20th. HC Wainwright raised their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a "buy" rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ADMA Biologics presently has an average rating of "Buy" and an average price target of $15.50.
Get Our Latest Analysis on ADMA Biologics
In related news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.